1.0IRLABhttps://irlab.se/sv/Nyemission 2025 - IRLABrich600338<blockquote class="wp-embedded-content" data-secret="Zq0LIVCkWt"><a href="https://irlab.se/sv/investerare/nyemission-2025/">Nyemission 2025</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://irlab.se/sv/investerare/nyemission-2025/embed/#?secret=Zq0LIVCkWt" width="600" height="338" title="”Nyemission 2025” – IRLAB" data-secret="Zq0LIVCkWt" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script type="text/javascript">
/* <![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
//# sourceURL=https://irlab.se/wp-includes/js/wp-embed.min.js
/* ]]> */
</script>
IRLAB växlar upp – Parkinsonfokus i bred pipeline med global potential Med fem projekt riktade mot olika centrala symtom vid Parkinsons sjukdom positionerar sig det svenska biofarmabolaget IRLAB som en innovativ och differentierad spelare inom neurodegenerativa sjukdomar. Genom en nyemission om cirka 136 miljoner kronor, varav 85 procent är garanterad, avser bolaget nu accelerera sina […]https://irlab.se/wp-content/uploads/2019/09/web_retina_DSF9408.jpg20481152